389 related articles for article (PubMed ID: 28875476)
1. Treatment of primary membranous nephropathy: where are we now?
Angioi A; Lepori N; López AC; Sethi S; Fervenza FC; Pani A
J Nephrol; 2018 Aug; 31(4):489-502. PubMed ID: 28875476
[TBL] [Abstract][Full Text] [Related]
2. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
[No Abstract] [Full Text] [Related]
3. Treatment of idiopathic membranous nephropathy.
Waldman M; Austin HA
J Am Soc Nephrol; 2012 Oct; 23(10):1617-30. PubMed ID: 22859855
[TBL] [Abstract][Full Text] [Related]
4. Clinical features, course and prognosis of idiopathic membranous nephropathy depending on the presence of antibodies against M-type phospholipase A2 receptor.
Jatem Escalante E; Segarra Medrano A; Carnicer Cáceres C; Martín-Gómez MA; Salcedo Allende MT; Ostos Roldan H; Agraz Pamplona I
Nefrologia; 2015; 35(5):479-86. PubMed ID: 26306972
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
6. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
7. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
8. Antiphospholipase A2 receptor autoantibody guided diagnosis and treatment of membranous nephropathy: a new personalized medical approach.
Glassock RJ
Clin J Am Soc Nephrol; 2014 Aug; 9(8):1341-3. PubMed ID: 25035274
[No Abstract] [Full Text] [Related]
9. Membranous nephropathy.
Mathieson PW
Clin Med (Lond); 2012 Oct; 12(5):461-6. PubMed ID: 23101149
[No Abstract] [Full Text] [Related]
10. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
Guerry MJ; Vanhille P; Ronco P; Debiec H
Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
[No Abstract] [Full Text] [Related]
11. Characterization of autoantibodies in primary membranous nephropathy and their clinical significance.
Stahl RA; Reinhard L; Hoxha E
Expert Rev Clin Immunol; 2019 Feb; 15(2):165-175. PubMed ID: 30433832
[No Abstract] [Full Text] [Related]
12. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
Brenchley PE
J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
[No Abstract] [Full Text] [Related]
13. [Anti-phospholipase A2 receptor (anti-PLA2R) antibodies and idiopathic membranous nephropathy: which role in diagnosis and prognosis of this disease?].
Netti GS; Ranieri E
G Ital Nefrol; 2014; 31(3):. PubMed ID: 25030016
[TBL] [Abstract][Full Text] [Related]
14. Treatment of membranous nephropathy: time for a paradigm shift.
Ruggenenti P; Fervenza FC; Remuzzi G
Nat Rev Nephrol; 2017 Sep; 13(9):563-579. PubMed ID: 28669992
[TBL] [Abstract][Full Text] [Related]
15. A Review of the Current Practice of Diagnosis and Treatment of Idiopathic Membranous Nephropathy in China.
Wu L; Lai J; Ling Y; Weng Y; Zhou S; Wu S; Jiang S; Ding X; Jin X; Yu K; Chen Y
Med Sci Monit; 2021 Feb; 27():e930097. PubMed ID: 33550324
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
Ishiwatari A; Wakai S; Shirakawa H; Honda K
Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
[TBL] [Abstract][Full Text] [Related]
17. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy.
Segarra-Medrano A; Jatem-Escalante E; Quiles-Pérez MT; Salcedo MT; Arbós-Via MA; Ostos H; Valtierra N; Carnicer-Cáceres C; Agraz-Pamplona I
Nefrologia; 2014 May; 34(3):353-9. PubMed ID: 24798555
[TBL] [Abstract][Full Text] [Related]
19. Successful Treatment of Patients With Refractory PLA
Klomjit N; Fervenza FC; Zand L
Am J Kidney Dis; 2020 Dec; 76(6):883-888. PubMed ID: 32311405
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological treatment of primary membranous nephropathy in 2016.
van de Logt AE; Hofstra JM; Wetzels JF
Expert Rev Clin Pharmacol; 2016 Nov; 9(11):1463-1478. PubMed ID: 27535699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
